This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Brain cancer	MicroRNA-17-92 (miR-17-92)	Cell culture and mouse studies suggest inhibiting miR-17-92 could help treat medulloblastoma. In a mouse model of medulloblastoma, miRNAs from the miR-17-92 cluster were overexpressed in medulloblastoma cells but not in normal cerebellum cells. In a mouse xenograft model of medulloblastoma, anti-miR-17 and anti-miR-19, which target miRNAs from the miR-17-92 cluster, decreased tumor proliferation and increased survival compared with saline. Next steps could include determining whether anti-miRNAs cross the blood brain barrier in patients with brain cancer or adopting new delivery strategies such as nanoparticles.	Patent and licensing status unavailable	Murphy, B.L. <i>et al. Cancer Res.</i> ; published online Oct. 21, 2013; doi:10.1158/0008-5472.CAN-13-0927 Contact: Martine F. Roussel, St. Jude Children's Research Hospital, Memphis, Tenn. e-mail: martine.roussel@stjude.org
<i>SciBX</i> 6(48); doi:10.1038/scibx.2013.1376 Published online Dec. 19, 2013				